|
gptkb:Troriluzole
|
Phase 3
|
|
gptkb:Aducanumab
|
Phase 3
|
|
gptkb:Pyrilutamide
|
Phase III (as of 2024)
|
|
gptkb:NPM1_gene
|
NPM1 mutation analysis for AML diagnosis
|
|
gptkb:Prospective_Comparison_of_ARNI_with_ACEI_to_Determine_Impact_on_Global_Mortality_and_Morbidity_in_Heart_Failure
|
gptkb:NCT01035255
|
|
gptkb:Janssen_COVID-19_vaccine
|
gptkb:ENSEMBLE_trial
|
|
gptkb:beloranib
|
gptkb:Prader-Willi_syndrome
|
|
gptkb:REACT_(Renal_Autologous_Cell_Therapy)
|
Phase 3
|
|
gptkb:Palforzia
|
gptkb:PALISADE
|
|
gptkb:ravidasvir/sofosbuvir
|
Phase III
|
|
gptkb:GAA_gene
|
available
|
|
gptkb:VWF
|
ristocetin cofactor activity
|
|
gptkb:NF1_gene
|
genetic testing available
|
|
gptkb:ciliary_neurotrophic_factor
|
gptkb:ALS
|
|
gptkb:cranial_nerve_IX
|
gag reflex
|
|
gptkb:tirzepatide
|
gptkb:SURMOUNT-2
|
|
gptkb:XL518
|
gptkb:NCT01596270
|
|
gptkb:Durvalumab
|
gptkb:PACIFIC_trial
|
|
gptkb:beloranib
|
Phase III (terminated)
|
|
gptkb:PRKAR1A
|
available
|